A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Dr. Todd Ellerin says the compounded pharmacy drugs are regulated on the state level, but most do not possess FDA regulation like brand name drugs ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback